
Managing canine osteoarthritis vs treating it
David Dycus, DVM, MS, CCRP, DACVS-SA, explains the difference between managing and treating canine osteoarthritis, and why early diagnosis and a standardized protocol can help give dogs more active years.
This episode is sponsored by Adequan Canine
David Dycus, DVM, MS, CCRP, DACVS-SA: Managing canine osteoarthritis [OA] vs treating it—yes, there is a difference. Mobility-related issues such as stiffness and soreness can be clinical signs of [OA]. Many of our current treatment strategies simply just address the pain, but the disease itself is still progressing. Adequan Canine, a polysulfated glycosaminoglycan, is the only treatment to help restore joint damage.
Veterinarians often think that we're treating [OA] through pain management, daily exercise, managing weight, and joint supplementation. While these things provide temporary pain relief, the disease itself is going to continue to progress unless we do something to treat it. What treating canine [OA] really means is getting to the root of the cause. Adequan Canine is the only FDA-approved treatment to help relieve joint inflammation, restore joint lubrication, and renew healthy joint cartilage. Adequan Canine is a disease-modifying OA treatment vs reactive pain management.
Early treatment matters. That's going to be the best way to give our canine friends more active years. It's important to know the early warning signs for an early OA diagnosis. Adequan Canine is the only treatment that will help slow the progression of disease vs simply just managing the pain. Your clients can take a quiz to help determine their dog's OA risk factors.
Analogies to help your clients better understand canine [OA] would simply be like putting air in a tire with a leak vs just repairing the tire so it can keep on rolling, or putting a bucket under a leak on a roof vs just repairing the roof itself.
Early diagnosis and treatment for canine [OA] starts with a standardized protocol. An OA protocol can help your clinic standardize the approach to the early diagnosis and treatment of canine [OA]. Request clinical resources at oaprotocolpack.com.
David Dycus, DVM, MS, CCRP, DACVS-SA, is a paid speaker for American Regent Animal Health.
Adequan® Canine polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL
Indications and Usage
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.
IMPORTANT SAFETY INFORMATION
Adequan® Canine should not be used in dogs who are hypersensitive to polysulfated glycosaminoglycan (PSGAG) or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, vomiting, anorexia, depression/lethargy, diarrhea, and in very rare cases death have also been reported. The safe use of PSGAG in breeding, pregnant, or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full
Related to this article









